The global microbiology testing market is projected to grow from USD 6.3 billion in 2025 to USD 13.7 billion by 2034, driven by increasing infectious disease prevalence, antimicrobial resistance concerns, and stringent regulatory requirements. North America leads with 42% market share, while Asia-Pacific is expected to record the fastest growth. Key drivers include technological advancements in molecular diagnostics, laboratory automation, and expanding clinical diagnostic infrastructure.

Becton Dickinson (BDX) has demonstrated a strong earnings-beat streak, with an average surprise of 3.78% over the last two quarters. The company currently has a positive Earnings ESP of +0.21% combined with a Zacks Rank #3 (Hold), suggesting another potential earnings beat in its November 5, 2026 report. Stocks with this combination historically beat consensus estimates nearly 70% of the time.

Becton, Dickinson and Company (BD) announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing expansion, including $3 billion toward manufacturing capacity. The company aims to increase domestically supplied essential medical consumables to 80% and manufacture all U.S.-used needles domestically with American-made steel. The agreement provides tariff protection on covered products, though financial impact remains unquantified pending finalization of tariff rates and implementation timing.

The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026.

The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region.

The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, AI automation, and aging demographics. The global medical supplies market is expected to reach $318.77 billion by 2031 with a 10% CAGR. However, tariffs, commodity inflation, and pharmaceutical pricing changes remain headwinds. Key industry players show mixed near-term prospects with the industry trading at favorable valuations compared to broader markets.

The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.

The global syringe filling machine market is projected to grow from USD 2.09 billion in 2026 to USD 2.99 billion by 2031 at a 7.41% CAGR. Growth is driven by rising demand for prefilled syringes, automated fill-finish lines for biologics, and regulatory focus on aseptic accuracy. Automated systems dominate with 63.92% market share, while servo-driven piston technology leads at 44.05%. Asia-Pacific emerges as the fastest-growing region at 10.72% CAGR, driven by biologics capacity expansion.

The global antimicrobial resistance surveillance market is projected to grow from USD 6.24 billion in 2025 to USD 8.66 billion by 2031, expanding at a 5.62% CAGR. Growth is driven by rising drug-resistant infections, government funding initiatives, and adoption of AI, molecular diagnostics, and genomic sequencing technologies. North America leads with 42.15% market share, while Asia-Pacific is the fastest-growing region at 6.41% CAGR. High implementation costs remain a challenge, particularly in resource-constrained settings.

The article recommends a buy-and-hold strategy for weathering inevitable bear markets, highlighting that the S&P 500 has historically recovered from all downturns. It suggests focusing on dividend-paying stocks in defensive sectors like healthcare and consumer staples, particularly Dividend Kings that have increased dividends for 50+ years, as these provide stability and income during market volatility.

The global apheresis market is projected to grow from USD 3.02 billion in 2026 to USD 4.41 billion by 2031, with a CAGR of 7.9%. Growth is driven by rising prevalence of autoimmune and neurological diseases, increased demand for plasma-derived therapies, and technological advances in automated systems. Disposables lead the product segment while plasmapheresis dominates procedures. North America holds the largest regional market share. Key challenges include high procedural costs and limited adoption in emerging markets.

The global blood transfusion diagnostics market is projected to grow from USD 4.88 billion in 2025 to USD 8.67 billion by 2035, with a CAGR of 5.91%. Growth is driven by increasing demand for automated testing, AI-driven blood safety solutions, molecular diagnostics, and rising prevalence of blood-related disorders. North America leads the market with 40.46% share, while Asia Pacific shows the fastest growth at 8.62% CAGR.